secwatch.observer — SEC 8-K summary
======================================

Issuer:     Orchestra BioMed Holdings, Inc. (OBIO)
CIK:        0001814114
Form:       8-K/A
Filed at:   2023-03-24T23:59:59+00:00
Accession:  0001213900-23-022800
Event type: other_material
Sentiment:  negative
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Orchestra BioMed reports 2022 net loss of $33.6M; revenue up to $3.5M from negative prior year
--------------------------------------------------------------------------------

- Net loss was $33.6M for 2022 vs $23.0M in 2021; operating expenses rose to $36.2M.
- Revenue of $3.5M included $2.9M partnership revenue; product revenue flat at $0.7M.
- Cash and marketable securities totaled $83.7M at Dec 31, 2022, up from $9.9M; funded by Series D preferred stock.
- Accumulated deficit reached $199.7M; management expects continued losses but has sufficient liquidity post-merger.
- Business combination with HSAC2 (SPAC) closed Jan 2023; audited financials now filed.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1814114/000121390023022800/0001213900-23-022800-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1814114/000121390023022800/ea175559-8ka1_orchestra.htm
  HTML page:      https://secwatch.observer/filing/0001213900-23-022800

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer